Sanofi-aventis to acquire BiPar Sciences, a US biopharmaceutical company
- Details
- Category: Sanofi
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) has signed a binding agreement for the acquisition of BiPar Sciences, Inc., ("BiPar") a privately held US biopharmaceutical company, developing novel tumorselective approaches for the treatment of different types of cancers.
Abbott Reports 16 Percent Earnings Growth in First Quarter
- Details
- Category: Abbott
Abbott has announced financial results for the first quarter ended March 31, 2009. Diluted earnings per share, excluding specified items, were $0.73, reflecting 15.9 percent growth, and $0.03 above the mid-point of Abbott's previous first-quarter guidance range. Diluted earnings per share under Generally Accepted Accounting Principles (GAAP) were $0.92, up 53.3 percent.
Roche Diabetes Care supports "Changing Diabetes in Children"
- Details
- Category: Roche
Roche will join forces with Novo Nordisk and the World Diabetes Foundation (WDF) in Novo Nordisk's five-year program called "Changing Diabetes in Children". Roche Diabetes Care will actively endorse humanitarian activities in this project which is starting in Tanzania, Uganda, Cameroon, Guinea-Conakry and the Democratic Republic of Congo.
FDA Advisory Committee Recommendation on Seroquel XR Supplemental New Drug Applications
- Details
- Category: AstraZeneca
On 8 April 2009, the U.S. Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee (PDAC) conducted a review of the safety and efficacy of supplemental new drug applications (sNDA) for SEROQUEL XR (quetiapine fumarate) extended-release tablets proposed for the treatment of major depressive disorder (MDD) and generalised anxiety disorder (GAD).
Genzyme to acquire the worldwide rights to Campath® (alemtuzumab) from Bayer HealthCare
- Details
- Category: Genzyme
Genzyme Corporation (Nasdaq: GENZ) has entered into an agreement to acquire the worldwide rights to Campath® (alemtuzumab) from Bayer HealthCare, giving Genzyme primary responsibility for the development and commercialization of this potential break-though treatment for multiple sclerosis (MS). Bayer will continue to fund a portion of alemtuzumab's development in MS and will retain an option to co-promote the product in MS upon approval.
The First Pharmaceutical Company for Protection of Human Rights in Clinical Research
- Details
- Category: Pfizer
Pfizer Inc announced has become the first pharmaceutical company to be accredited by the Association for the Accreditation of Human Research Protection Programs (AAHRPP) for ensuring the protection of human subjects taking part in early-stage clinical trials.
Pfizer Development Pipeline Shows Advances In High-Priority Disease Areas
- Details
- Category: Pfizer
Pfizer Inc has provided an update to its pipeline, highlighting the progression of clinical programs in high-priority therapeutic areas, and announced the start of Phase 3 clinical trials for two new molecular entities. In total, the company initiated seven Phase 3 programs within the past six months.
More Pharma News ...
- GSK submits Tyverb®/Tykerb® for first-line treatment of metastatic breast cancer in Europe, US
- Significantly More Patients With Cardiovascular Disease Quit Smoking Using Chantix/Champix®
- Bayer Crop Science and the French research organization CNRS intensify collaboration
- Novartis makes an open offer to increase stake in Novartis India Ltd.
- HemCon Medical Technologies, Inc. Announces Improved Results from Live Nail Infection Study
- EMERFLU®, pandemic influenza vaccine for humans, approved in Australia
- Glivec® recommended for use in Europe as first post-surgery treatment for GIST